Spots Global Cancer Trial Database for The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Official Title: Immunogenicity and Safety of Concomitant Inoculation of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia Coli) and Measles Mumps and Rubella Combined Vaccine, Live

Study ID: NCT05279248

Conditions

Human Papilloma Virus Infection Type 16

Human Papilloma Virus Infection Type 18

Measles

Rubella

Mumps

Interventions

HPV+MMR（0d），HPV（6m）

HPV（0d），HPV（6m），MMR（7m）

MMR（0d），HPV（1m），HPV（7m）

Study Description

Brief Summary: The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles Mumps and Rubella Combined Vaccine, Live（MMR）

Detailed Description: Main subjects: To evaluate the immunogenicity of HPV vaccine and MMR vaccine at the same time but at different sites as not inferior to vaccination of HPV vaccine or MMR vaccine alone. Secondary subjects: To evaluate the safety of simultaneous administration of HPV vaccine and MMR vaccine.